Case Report
Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity
Table 1
Multiple myeloma treatment summary with relevant clinical and laboratory parameters.
| | 5/23/2013 Prechemotherapy | 6/18/2013 VCD, 1 cycle | 8/6/2013 VCD, 3 cycles Change to RVD | 10/1/2013 RVD, 2 cycles | 12/3/2013 RVD, 4 cycles | 12/30/2013 RVD, 5 cycles |
| IgA (mg/dL) | 1758 | 2358 | 2130 | 1377 | 885 | 492 | M Spike (g/dL) | 2.91 | 2.7 | 2.0 | 2.0 | 1.2 | 0.7 | BUN (mg/dL) | 16 | 22 | 25 | 19 | 11 | 11 | Creatinine (mg/dL) | 0.95 | 1.0 | 1.2 | 0.9 | 0.9 | 0.9 | 24-hour urine protein (g) | 19.8 | | 2.4 | | 0.78 | 1.0 | Blood pressure (mmHg) | 127/72 | 119/58 | 108/63 | 120/66 | 107/67 | 117/69 | Pulse (bpm) | 80 | 60 | 75 | 63 | 71 | 69 |
|
|